Download full report with analyst certification and important disclosures
Feb 11 2020, 06:30 GMT
Ratings and price correct at time of issue
Company | Rating | Date | Previous Rating | Date | Closing Price |
---|---|---|---|---|---|
DSM-Firmenich | OUTPERFORM | 11/02/15 | Neutral | 16/07/14 | 11500c |
Givaudan | NEUTRAL | 21/06/12 | N/A | N/A | 326600chf |
Kerry Group | OUTPERFORM | 30/06/09 | N/A | N/A | 11650c |
Symrise | NEUTRAL | 15/01/19 | Outperform | 21/06/12 | 9660c |
While the outbreak of coronavirus across China has been well-documented, its economic impact remains under-appreciated by the market. Inter-connected supply chains are likely to amplify the first-round effects, with the impact on upstream activities a potential blind spot for investors. For now, the market appears to be pricing in short-term revenue dislocation, while ignoring secondary effects (working capital, operating leverage, etc). We believe that the outbreak will impact sector-wide organic growth rates in Q1 at a minimum.
Feb 11 2020, 06:30 GMT